Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO Italy 2020 | Multiple myeloma: ADCs and BiTEs

Hans Lee • 18 Sep 2020
SOHO Italy 2020
Multiple Myeloma AMG 420 Antibodies Belantamab mafodotin BiTEs CC-93269 Teclistamab
DREAMM-2

Hans Lee, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the current role of antibody-drug conjugates (ADCs) and bi-specific antibodies in multiple myeloma, including belantamab mafodotin, an antibody-drug conjugate, recently approved in the U.S by the FDA for the treatment of relapsed/refractory multiple myeloma and highlights the ocular toxicities associated with this therapy. Dr Lee also discusses bi-specific antibodies as an exciting, off-the-shelf approach to the treatment of multiple myeloma, including the BiTE, AMG-420, CC-93269, and teclistamab. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Hans Lee

2:57
LINKER-MM1: promising safety and efficacy of linvoseltamab in R/R multiple myeloma
Hans Lee • 10 Dec 2023
5:14
LINKER-MM1: linvoseltamab in patients with R/R multiple myeloma
Hans Lee • 4 Jun 2023
2:12
Risk of infection and mitigation strategies in patients with myeloma treated with bispecifics
Hans Lee • 4 Jun 2023
1:47
Role of BCMA-targeting ADCs in the management of myeloma
Hans Lee • 4 Jun 2023

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals